Key facts
- This page summarizes BAKER BROS. ADVISORS LP's Form 4 filing for INCYTE CORP (INCY).
- 4 reported transactions and 12 derivative rows are listed below.
- Accepted by SEC: 10 Jun 2026, 16:41.
BAKER BROS. ADVISORS LP - 08 Jun 2026 Form 4 Insider Report for INCYTE CORP (INCY)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- INCY
- Reported as of
- 08 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2026, 16:41:15 UTC
- Prior SEC filing
- 05 Jun 2026
- Next SEC filing
- 10 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
BAKER BROS. ADVISORS LP filed Form 4 for INCYTE CORP (INCY) on 10 Jun 2026.
Change
- Previous filing in this sequence was filed on 05 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (6)
CIK 0001263508
Primary reporting owner
BAKER BROS. ADVISORS LP
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
- Signature date
- 10 Jun 2026
CIK 0001551139
667, L.P.
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
- Signature date
- 10 Jun 2026
CIK 0001580575
Baker Bros. Advisors (GP) LLC
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- /s/ Julian C. Baker
- Signature date
- 10 Jun 2026
CIK 0001363364
Baker Brothers Life Sciences LP
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
- Signature date
- 10 Jun 2026
CIK 0001087940
BAKER FELIX
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P.,pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., /s/ Name: Scott L. Lessing, Title: President
- Signature date
- 10 Jun 2026
CIK 0001087939
BAKER JULIAN
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- /s/ Felix J. Baker
- Signature date
- 10 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.06%
- Price
- $0.000000*
- Shares after
- 2,834,681
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.06%
- Price
- $0.000000*
- Shares after
- 2,834,681
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.06%
- Price
- $0.000000*
- Shares after
- 2,834,681
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.06%
- Price
- $0.000000*
- Shares after
- 2,834,681
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.06%
- Price
- $0.000000*
- Shares after
- 2,834,681
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.06%
- Price
- $0.000000*
- Shares after
- 2,834,681
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.01%
- Price
- $0.000000*
- Shares after
- 28,205,360
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8, F9
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.01%
- Price
- $0.000000*
- Shares after
- 28,205,360
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8, F9
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.01%
- Price
- $0.000000*
- Shares after
- 28,205,360
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8, F9
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.01%
- Price
- $0.000000*
- Shares after
- 28,205,360
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8, F9
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.01%
- Price
- $0.000000*
- Shares after
- 28,205,360
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8, F9
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,642
- Change %
- +0.01%
- Price
- $0.000000*
- Shares after
- 28,205,360
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8, F9
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 Jun 2026
- Ownership
- Direct
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F12
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F12
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F12
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F12
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F12
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F12
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F2, F3, F4, F6, F7, F8, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F2, F3, F4, F6, F7, F8, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F2, F3, F4, F6, F7, F8, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F2, F3, F4, F6, F7, F8, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F2, F3, F4, F6, F7, F8, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F2, F3, F4, F6, F7, F8, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F3, F4, F6, F7, F8, F9, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F3, F4, F6, F7, F8, F9, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F3, F4, F6, F7, F8, F9, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F3, F4, F6, F7, F8, F9, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F3, F4, F6, F7, F8, F9, F13
INCY
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +6,111
- Change %
- Price
- $0.000000*
- Shares after
- 6,111
- Date
- 08 Jun 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,111
- Exercise price
- $100.64
- Footnotes
- F3, F4, F6, F7, F8, F9, F13
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 13 footnotes
Footnote F1
Includes 1,642 restricted stock units (each an "RSU") payable solely in common stock ("Common Stock") of Incyte Corporation (the "Issuer") granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), on June 8, 2026, pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Incentive Plan"). The RSUs fully vest on the earlier of June 8, 2027, the date of the next annual meeting of stockholders of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.
Footnote F2
After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the non-qualified options to purchase Common Stock of the Issuer ("Stock Options") reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Footnote F3
Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.
Footnote F4
Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Footnote F5
Includes beneficial ownership of 15,105 shares of Common Stock previously issued to Julian C. Baker pursuant to the Incentive Plan in lieu of director retainer fees, 14,722 shares of Common Stock received previously from vested RSUs and 245,000 shares of Common Stock received previously from the exercise of 245,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, each of which the Funds are deemed to own a portion.
Footnote F6
Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.
Footnote F7
Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
Footnote F8
The acquisitions of the RSUs and Stock Options reported on this form represent grants to Julian C. Baker of 1,642 RSUs on Table I and 6,111 Stock Options on Table II. These grants of 1,642 RSUs and 6,111 Stock Options for Julian C. Baker are reported for each of the Funds as each has an indirect pecuniary interest in such securities.
Footnote F9
After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Footnote F10
Common Stock directly held by Julian C. Baker.
Footnote F11
Common Stock directly held by Felix J. Baker.
Footnote F12
Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in 33,410 shares of Common Stock directly held by FBB Associates. Julian C. Baker and Felix J. Baker are the sole partners of FBB Associates. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Julian C. Baker or Felix J. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Footnote F13
Includes 6,111 Stock Options granted by the Issuer to Julian C. Baker on June 8, 2026, pursuant to the Incentive Plan. The Stock Options have a strike price of $100.64 and vest on the earlier of June 8, 2027, the date of the next annual meeting of stockholders of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the Board through the vesting date. The Stock Options expire on June 7, 2036.
SEC remarks
Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Incyte Corporation (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Julian C. Baker are deemed directors by deputization of the Issuer.